Teladoc Inc (NYSE:TDOC) – Equities researchers at William Blair boosted their FY2017 earnings per share (EPS) estimates for shares of Teladoc in a report issued on Monday, Zacks Investment Research reports. William Blair analyst R. Daniels now expects that the health services provider will post earnings per share of ($1.54) for the year, up from their previous forecast of ($1.55). William Blair also issued estimates for Teladoc’s Q4 2017 earnings at ($0.39) EPS, Q1 2018 earnings at ($0.31) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.30) EPS, FY2018 earnings at ($1.15) EPS and FY2019 earnings at ($0.79) EPS.
A number of other brokerages also recently issued reports on TDOC. Canaccord Genuity upped their price objective on Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday. ValuEngine upgraded Teladoc from a “sell” rating to a “hold” rating in a research note on Friday. Citigroup initiated coverage on Teladoc in a research report on Thursday, January 4th. They set a “buy” rating on the stock. KeyCorp restated a “buy” rating and issued a $39.00 target price on shares of Teladoc in a research note on Monday, December 4th. Finally, Jefferies Group assumed coverage on Teladoc in a research report on Friday, January 26th. They set a “buy” rating and a $40.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $39.43.
Shares of Teladoc (NYSE TDOC) traded down $1.75 during trading hours on Wednesday, reaching $35.30. The company’s stock had a trading volume of 1,340,554 shares, compared to its average volume of 1,090,000. The company has a market cap of $2,140.00 and a P/E ratio of -24.34. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08. Teladoc has a 52-week low of $19.60 and a 52-week high of $38.40.
In other news, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $3,299,000.00. Following the completion of the transaction, the chief executive officer now owns 718,261 shares in the company, valued at approximately $23,695,430.39. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Mark Hirschhorn sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $32.99, for a total value of $989,700.00. Following the completion of the transaction, the chief financial officer now owns 5,203 shares of the company’s stock, valued at approximately $171,646.97. The disclosure for this sale can be found here. Company insiders own 4.47% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Teladoc in the 4th quarter valued at approximately $101,000. ETF Managers Group LLC purchased a new position in Teladoc during the second quarter valued at $104,000. Pacad Investment Ltd. purchased a new position in Teladoc during the second quarter valued at $135,000. Fred Alger Management Inc. purchased a new position in Teladoc during the second quarter valued at $139,000. Finally, Ameritas Investment Partners Inc. raised its stake in Teladoc by 134.2% during the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after buying an additional 2,707 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/03/fy2017-eps-estimates-for-teladoc-inc-boosted-by-analyst-tdoc.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Get a free copy of the Zacks research report on Teladoc (TDOC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.